The FDA has asked Novartis for more information on its gouty arthritis drug canakinumab. The regulator’s request came in a …
Novartis says its COPD treatment has shown significant benefits over two established rivals, and could form the cornerstone of a …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer

